EndLyz Therapeutics

Neurodegenerative diseases like Parkinson’s affect millions worldwide, placing immense burdens on patients, caregivers, and healthcare systems.

EndLyz is developing disease-modifying oral small-molecule therapies that restore endo-lysosomal function – the cell’s internal ‘recycling’ system. By fixing this core dysfunction, particularly in neuronal cells, its approach aims to slow or even halt the progression of neurodegenerative diseases.